Wellington Management Group LLP Acquires 221,851 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Wellington Management Group LLP lifted its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 2.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,769,771 shares of the company's stock after acquiring an additional 221,851 shares during the period. Wellington Management Group LLP owned 13.58% of Structure Therapeutics worth $341,015,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. FMR LLC lifted its position in shares of Structure Therapeutics by 6.7% during the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company's stock valued at $268,977,000 after acquiring an additional 383,635 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Structure Therapeutics by 18.0% during the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company's stock worth $173,623,000 after purchasing an additional 602,609 shares during the period. Driehaus Capital Management LLC lifted its holdings in shares of Structure Therapeutics by 3.5% during the second quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company's stock valued at $101,204,000 after purchasing an additional 86,833 shares during the last quarter. Federated Hermes Inc. boosted its position in shares of Structure Therapeutics by 6.6% in the 2nd quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company's stock valued at $94,531,000 after purchasing an additional 150,000 shares during the period. Finally, Point72 Asset Management L.P. boosted its position in shares of Structure Therapeutics by 196.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company's stock valued at $54,348,000 after purchasing an additional 820,589 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Stock Up 6.8 %

NASDAQ:GPCR traded up $2.11 during trading hours on Friday, reaching $33.35. The company had a trading volume of 830,099 shares, compared to its average volume of 790,990. Structure Therapeutics Inc. has a one year low of $26.61 and a one year high of $62.85. The stock has a 50-day moving average of $37.29 and a two-hundred day moving average of $39.33. The firm has a market capitalization of $1.91 billion, a PE ratio of -45.07 and a beta of -3.41.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on GPCR shares. Morgan Stanley initiated coverage on Structure Therapeutics in a research report on Monday, September 23rd. They set an "overweight" rating and a $118.00 price objective for the company. HC Wainwright started coverage on Structure Therapeutics in a report on Wednesday. They issued a "buy" rating and a $80.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, September 23rd. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $85.67.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.